Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture.
The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
The life science world has continued to deepen its interest in the digital space. While the mainstream life science news of the year was research on the coronavirus vaccine, when it came to digital the industries efforts were more varied. We saw new partnerships between pharma and digital health around topics such as respiration health, cardiovascular conditions and real-world data.
This year we...
Novartis is teaming up with smartpatient to launch a new app feature on the MyTherapy app for patients with wet macular degeneration (AMD) that is focused on educating patients and caregivers about treatment and management.
Called "See What’s Next," the section was specifically designed to help provide patients and their families with resources about navigating life with the disease and giving...
Novartis's digital strategy hasn't changed too much since MobiHealthNews spoke with the pharma company in 2018. But, at the HLTH virtual conference this week, Novartis Chief Digital Officer Betrand Bodson reiterated the company's four-part strategy, focusing especially on its partnerships, including those with Microsoft, Amazon and China's Tencent.
"We started this agenda in earnest two and a...
Digital respiratory health company Propeller Health is expanding its geographical footprint to Japan thanks to a partnership with pharma giant Novartis.
Patients living in Japan who take one of Novartis’ drugs to help with uncontrolled asthma, the Enerzair or Atectura Breezhaler, will be able to enroll in Propeller’s digital-management program.
Those that opt in can attach the Propeller’s...
Novartis and respiratory health company Propeller Health, a ResMed subsidiary, have teamed up to co-package the latter’s digital health platform with the pharma giant’s new asthma medication Enerzair Breezhaler.
This news come shortly after the product landed European Commission clearance. The co-packaged product will be launching in the EU during 2020. However, it is not yet available in the U....
FDA begins sharing patient's cancer drug experiences. The FDA's Oncology Center of Excellence has kicked off the first step of new pilot program that will increase the availability of patient-reported outcome data from cancer clinical trials. Project Patient Voice, as it's called, will start with making the data from a single trial accessible online while the agency solicits public feedback, but...
Following numerous reports of underperforming COVID-19 antibody tests, the FDA has raised the bar for these products in a revision to its emergency testing policy.
As of today, commercial manufacturers that notify the agency of their intent to submit a test for Emergency Use Authorization are required to do so within 10 business days from the date of notification. Further, the FDA has recommended...
International pharma giant Novartis announced this morning the acquisition of Amblyotech, a startup that combines 3D glasses and video game software to treat amblyopia, more commonly known as "lazy eye." The terms of the deal were not disclosed.
Novartis also said that it will be developing new games and kicking off a proof-of-concept study alongside major French video game publisher Ubisoft and...
It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...
